US · Technology · Scientific & Technical Instruments
EPS came in at 0.02 against a street estimate of 0.05 — a miss of 60.0%.
Analysts rate Sono-Tek Corp a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $8.50.
MIXED Sono-Tek delivered first-half growth and stronger margins, led by medical systems, while Q2 EPS missed the street and fiscal 2027 revenue guidance remained only flat to modest growth. Q2 FY27 No regional revenue percentages or geographic sales trends were discussed in the call. Analysts focused on integrated production orders, medical-device expansion, engineering capacity, and facility capacity. Management emphasized follow-on orders, broader implantable-device applications, and continued investment. 2026-10-14…
Full summary in the app.
| Fund | Stake |
|---|---|
| Vanguard Capital Management, LLC | 2.37% |
| Geode Capital Management, LLC | 0.95% |
| Renaissance Technologies Corp | 0.73% |
| M&T Bank Corp | 0.51% |
| Morgan Stanley - Brokerage Accounts | 0.44% |
| Vanguard Fiduciary Trust Co | 0.43% |
| Stifel Financial Corp | 0.38% |
| Bard Associates Inc | 0.36% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sono-Tek Corp — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.